#USA #San Jose #Intalight #DREAM OCT #Optical Coherence

Intalight™ Achieves CE Mark Approval for its Advanced DREAM OCT™ Imaging System

San Jose, California - In a remarkable stride in ophthalmic technology, Intalight™, a pioneering force in Optical Coherence Tomography (OCT), has successfully secured CE mark approval for its innovative DREAM OCT™ platform. This milestone not only marks a significant achievement for the company but also opens doors for European ophthalmologists to leverage state-of-the-art imaging technology in their practice.

The CE mark signifies the European Union's endorsement of DREAM OCT for commercial use, allowing Intalight to bring its advanced imaging capabilities to a broader market. The acronym DREAM encapsulates key features of this cutting-edge imaging system: Deep imaging depth, Rapid sweeping speed, Extensive scan range, Accurate results, and Multimodal imaging capabilities. These characteristics combine to deliver the highest quality OCT images available today.

Enhanced Imaging Capabilities

The capabilities of the DREAM OCT™ platform are truly impressive. One of its standout features is the ability to generate ultra-wide field imaging in a single scan, producing a 130° OCTA image. This is complemented by swept-source technology that enables exceptional penetration through ocular opacities, whether located in the lens or the vitreous, ensuring that clinicians obtain clear and comprehensive images necessary for diagnosis and treatment.

Shawn Peng, Intalight’s chairman and founder, expressed his pride in achieving CE mark approval. He stated, “This achievement allows us to provide ophthalmologists in Europe with state-of-the-art technology that delivers improved results for their patients.” The DREAM OCT's sweeping source technology showcases its advanced 12 mm super-depth scanning capabilities, crucial for detailed imaging of the choroid, retina, and a significant portion of the vitreous cavity. In addition, the platform’s super-depth anterior scanning achieves 16.2 mm in air, enabling the capture of the complete anterior segment from the cornea to the anterior part of the vitreous in just one scan.

Meeting Clinician Needs

The demand for efficient and accurate imaging solutions has driven the development of DREAM OCT. Bing Li, Intalight’s CEO and Co-Founder, noted that eye care professionals have long needed a solution that delivers speed, accuracy, and depth. The DREAM OCT platform not only meets these demands but also integrates multiple imaging modalities, crucial for addressing complex clinical scenarios that retina specialists and comprehensive ophthalmologists face.

With over 160 peer-reviewed studies published utilizing data from DREAM OCT devices, the platform has already proven itself a valuable tool in clinical and research settings.

Looking Ahead

The CE mark approval in Europe is just the beginning for Intalight. Joe Garibaldi, the Chief Commercial Officer of Intalight, remarked, “This is such exciting news for Intalight that there's no more waiting in Europe, and we look forward to being able to provide this innovative solution in the US.” With its eyes set on expanding its market reach, Intalight aims to work closely with leading academic institutions and private practices in both the U.S. and Europe, bolstered by this recent success.

About Intalight

Founded by a group of scientists and seasoned industry veterans, Intalight Inc. has centered its mission on developing the most sophisticated ophthalmic technologies available. With facilities in Silicon Valley, Shanghai, and Luoyang, the company is committed to advancing the field of ophthalmology through innovative solutions like the DREAM OCT™ device. This crucial imaging technology is rapidly becoming indispensable, enhancing both the clinical examination and research capabilities of ophthalmologists worldwide.

For further information about Intalight and its groundbreaking DREAM OCT™ platform, visit Intalight’s website and connect with the company on LinkedIn and Facebook.